American Century Companies Portfolio holdings
American Century Companies, Inc., founded in 1958 by James E. Stowers Jr. as Twentieth Century Mutual Funds and headquartered in Kansas City, Missouri, is a privately held investment management firm renowned for its focus on delivering investment results to clients while supporting medical research. Starting with just $100,000 from 24 shareholders, it rebranded to American Century Investments in 1997 and now manages hundreds of billions in assets across mutual funds, ETFs, and institutional portfolios, emphasizing no-load funds and a client-centric approach. The firm’s unique ownership structure sees over 40% of its profits funneled to the Stowers Institute for Medical Research, which it majority-owns, funding groundbreaking biomedical research, while Nomura Holdings holds a significant minority stake. With a global presence in cities like New York, London, and Hong Kong, and a workforce of around 1,400, American Century blends financial expertise with a mission to improve lives through both wealth creation and scientific advancement.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$493M |
| 2 |
Colgate-Palmolive
CL
|
+$367M |
| 3 |
Microsoft
MSFT
|
+$328M |
| 4 |
Fidelity National Information Services
FIS
|
+$298M |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
WP
Worldpay, Inc.
WP
|
+$300M |
| 2 |
CXO
CONCHO RESOURCES INC.
CXO
|
+$268M |
| 3 |
Medtronic
MDT
|
+$233M |
| 4 |
Intercontinental Exchange
ICE
|
+$201M |
| 5 |
STI
SunTrust Banks, Inc.
STI
|
+$187M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.66% |
| 2 | Technology | 16% |
| 3 | Healthcare | 15% |
| 4 | Consumer Discretionary | 11.58% |
| 5 | Industrials | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Manhattan Associates
MANH
$11.2B
| $2.92M | ﹤0.01% |
36,219
+1,264
| +4% | +$101K |
|
|
MLPI
902
DELISTED
UBS E-TRACS Alerian MLP Infrastructure ETN
MLPI
| $2.91M | ﹤0.01% |
+139,642
| New | +$2.99M |
|
903
Anika Therapeutics
ANIK
$295M
| $2.91M | ﹤0.01% |
52,958
-15,050
| -22% | -$773K |
|
904
The RMR Group
RMR
$337M
| $2.9M | ﹤0.01% |
63,832
+56,472
| +767% | +$2.66M |
|
905
Universal Electronics
UEIC
$75.8M
| $2.9M | ﹤0.01% |
57,038
+38,296
| +204% | +$1.7M |
|
|
ESPR
906
DELISTED
Esperion Therapeutics
ESPR
| $2.89M | ﹤0.01% |
78,845
+18,596
| +31% | +$737K |
|
907
Toro Company
TTC
$9.32B
| $2.87M | ﹤0.01% |
39,214
-6,842
| -15% | -$489K |
|
|
CVET
908
DELISTED
Covetrus, Inc. Common Stock
CVET
| $2.87M | ﹤0.01% |
241,508
-1,866,595
| -89% | -$34.6M |
|
909
Autodesk
ADSK
$52.7B
| $2.86M | ﹤0.01% |
19,382
-624,868
| -97% | -$97.2M |
|
910
Quaker Houghton
KWR
$2.91B
| $2.86M | ﹤0.01% |
+18,107
| New | +$3.1M |
|
911
Ironwood Pharmaceuticals
IRWD
$714M
| $2.85M | ﹤0.01% |
331,912
+42,211
| +15% | +$410K |
|
912
Elastic
ESTC
$8.02B
| $2.84M | ﹤0.01% |
34,523
-5,340
| -13% | -$475K |
|
913
Ultragenyx Pharmaceutical
RARE
$2.65B
| $2.82M | ﹤0.01% |
65,842
+2,947
| +5% | +$160K |
|
914
Vanda Pharmaceuticals
VNDA
$314M
| $2.8M | ﹤0.01% |
+210,540
| New | +$2.93M |
|
915
Insperity
NSP
$1.92B
| $2.78M | ﹤0.01% |
28,197
+1,742
| +7% | +$189K |
|
|
AIMT
916
DELISTED
Aimmune Therapeutics
AIMT
| $2.78M | ﹤0.01% |
132,793
-27,638
| -17% | -$564K |
|
917
Charter Communications
CHTR
$17.9B
| $2.78M | ﹤0.01% |
6,737
+2,942
| +78% | +$1.19M |
|
|
OPTN
918
DELISTED
OptiNose
OPTN
| $2.77M | ﹤0.01% |
26,420
+6,204
| +31% | +$619K |
|
919
Rollins
ROL
$17.6B
| $2.76M | ﹤0.01% |
121,509
-3,462
| -3% | -$79.5K |
|
920
Veracyte
VCYT
$3.59B
| $2.74M | ﹤0.01% |
114,057
+11,395
| +11% | +$303K |
|
921
Enanta Pharmaceuticals
ENTA
$393M
| $2.73M | ﹤0.01% |
+45,504
| New | +$3.38M |
|
922
AES
AES
$10.5B
| $2.73M | ﹤0.01% |
166,860
-318,758
| -66% | -$5.13M |
|
923
Perdoceo Education
PRDO
$1.96B
| $2.71M | ﹤0.01% |
170,825
+78,146
| +84% | +$1.53M |
|
924
Voyager Therapeutics
VYGR
$197M
| $2.69M | ﹤0.01% |
156,234
+25,103
| +19% | +$527K |
|
|
SIVB
925
DELISTED
SVB Financial Group
SIVB
| $2.67M | ﹤0.01% |
12,772
+4,606
| +56% | +$965K |
|
Similar funds
American Century Companies's Q3 2019 Portfolio in Review
As of Q3 2019, American Century Companies held 1,407 positions worth $99.6B, down 0.83% from $100B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
American Century Companies's Q3 2019 filing shows 144 new, 546 increased, 497 reduced and 204 closed positions. Its largest new stake was A.O. Smith: 2,750,567 shares worth $131M. The largest sale was Worldpay, Inc., an estimated $300M.
By sector, the portfolio is most concentrated in Financials at 17% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
- American Century Companies's largest Q3 2019 buy was A.O. Smith: 2,750,567 shares worth $131M.
- American Century Companies added most to Pfizer in Q3 2019, an estimated $493M increase.
- American Century Companies's biggest Q3 2019 reduction was Medtronic, cutting an estimated $233M.
- American Century Companies fully exited Worldpay, Inc. in Q3 2019, selling an estimated $300M.
- American Century Companies's ten largest holdings make up 18% of its $99.6B portfolio in Q3 2019.
- American Century Companies opened 144 new positions and closed 204 in Q3 2019.
- American Century Companies's portfolio value fell 0.83% quarter-over-quarter to $99.6B.
Based on American Century Companies's 13F filing for Q3 2019, filed 13 Nov 2019.